Gritstone Oncology files for $80M IPO by Amirah Al Idrus Thursday, August 23, 2018 After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
Gritstone, BMS to trial immunotherapy combos in solid tumors by Amirah Al Idrus Thursday, July 19, 2018 Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
ASCO: Mixed reaction to BMS, Nektar’s high stakes I-O trial by Phil Taylor Sunday, June 3, 2018 Nektar’s much-anticipated data from a study pairing its NKTR-214 with Bristol-Myers Squibb’s Opdivo have resulted in a lot of head-scratching.
Apexigen poaches Bristol executive to lead antibody discovery by Conor Hale Friday, May 18, 2018 Frances Rena Bahjat, BMS’ former director of in vivo studies, joined Apexigen in a newly created role.
Nektar slips on reduced response rates for Opdivo combo by Amirah Al Idrus Thursday, May 17, 2018 The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Jounce plunges after ASCO abstract reveal by Phil Taylor Thursday, May 17, 2018 Jounce shares fall after publication of an ASCO abstract giving initial data from a trial of its first-in-class ICOS inhibitor JTX-2011.
X4’s I-O combo pilot shows new activity compared to Opdivo alone by Conor Hale Tuesday, May 15, 2018 A pilot showed X4’s anti-PD-1 combination spurred activity in patients that didn’t respond to Opdivo treatment alone, with a drug bought from Sanofi.
Ziopharm hits pause on planned pivotal brain cancer trial by Nick Paul Taylor Friday, May 11, 2018 Management took the action after technical issues slowed progress of the inducible adenoviral vector.
Lilly boosts immuno-oncology pipeline with $1.6B Armo buy by Amirah Al Idrus Thursday, May 10, 2018 Eli Lilly is acquiring Armo Biosciences and its lead asset, a PEGylated form of the cytokine IL-10, for $1.6 billion.
Incyte wipes out late-phase epacadostat program by Nick Paul Taylor Tuesday, May 1, 2018 Incyte is downgrading two pivotal epacadostat-Keytruda trials to phase 2 studies and backing away from six other late-stage tests of its IDO drug.